Haloperidol plasma levels and clinical response in paranoid schizophrenics

The relationship between haloperidol plasma levels, plasma prolactin, and therapeutic efficacy was evaluated in 20 paranoïd schizophrenics in a fixed-dose study for 6 weeks. We found a significant intrapatient cross-correlation of therapeutic efficacy, as measured by decrease in MSS and BPRS rating...

Full description

Saved in:
Bibliographic Details
Published in:European Archives of Psychiatry and Neurological Sciences 1984-01, Vol.234 (4), p.231-236
Main Authors: LINKOWSKI, P, HUBAIN, P, VON FRENCKELL, R, MENDLEWICZ, J
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Female
Haloperidol - blood
Haloperidol - therapeutic use
Humans
Kinetics
Male
Medical sciences
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Prolactin - blood
Psychiatric Status Rating Scales
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychometrics
Psychopharmacology
Schizophrenia, Paranoid - blood
Schizophrenia, Paranoid - drug therapy
Schizophrenia, Paranoid - psychology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The relationship between haloperidol plasma levels, plasma prolactin, and therapeutic efficacy was evaluated in 20 paranoïd schizophrenics in a fixed-dose study for 6 weeks. We found a significant intrapatient cross-correlation of therapeutic efficacy, as measured by decrease in MSS and BPRS rating scales and time-dependent haloperidol and prolactin changes, which were tested at weekly intervals. However, no significant curvilinear relationship was present between steady-state haloperidol plasma levels and MSS and BPRS improvement scores. Our data do not furnish clear-cut evidence in favor of the existence of a therapeutic window for haloperidol plasma levels in paranoïd schizophrenia.
ISSN:0175-758X
1433-8491
DOI:10.1007/BF00381354